open access

Vol 81, No 6 (2010)
ARTICLES
Get Citation

Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer

Bożena Dobrzycka, Sławomir Jerzy Terlikowski, Marcin Kwiatkowski, Magdalena Grabowicz, Maciej Kinalski, Lech Chyczewski
Ginekol Pol 2010;81(6).

open access

Vol 81, No 6 (2010)
ARTICLES

Abstract

Abstract Background: Angiogenesis is of crucial importance for endometrial tumor growth and Vascular Endothelial Growth Factor (VEGF) is the key mediator of angiogenesis. Objective: The purpose of our study was to assess the prognostic value of VEGF and its receptors in relation to endometrioid endometrial carcinomas. Material and methods: In this study, we conducted an immunohistochemical evaluation of VEGF and VEGFRs expression in 84 tissue samples obtained from endometrioid endometrial cancer patients undergoing curative surgical treatment. Results: Out of 84 cancers, strong positive expression of VEGF was seen in 35 (42%) tumors. The overall strong positive rates were 33% for VEGFR-1 and for 15% for VEGFR-2. There was a significant correlation between clinical stage and VEGF and VEGFR-1 overexpression (p=0.027 and p=0.004, respectively). Additionally, there was a significant correlation between histological grade and VEGF and VEGFR-1 overexpression (p<0.001 and p<0.001, respectively). The 5-year DFS of patients with VEGF and VEGFR-1 overexpression was significantly lower than that of those with a weakly positive or negative tumor (p<0.001). Conclusion: Immunohistochemical evaluation of VEGF and VEGFR-1 overexpression may be a useful marker for predicting 5-year DFS in endometrioid endometrial cancer.

Abstract

Abstract Background: Angiogenesis is of crucial importance for endometrial tumor growth and Vascular Endothelial Growth Factor (VEGF) is the key mediator of angiogenesis. Objective: The purpose of our study was to assess the prognostic value of VEGF and its receptors in relation to endometrioid endometrial carcinomas. Material and methods: In this study, we conducted an immunohistochemical evaluation of VEGF and VEGFRs expression in 84 tissue samples obtained from endometrioid endometrial cancer patients undergoing curative surgical treatment. Results: Out of 84 cancers, strong positive expression of VEGF was seen in 35 (42%) tumors. The overall strong positive rates were 33% for VEGFR-1 and for 15% for VEGFR-2. There was a significant correlation between clinical stage and VEGF and VEGFR-1 overexpression (p=0.027 and p=0.004, respectively). Additionally, there was a significant correlation between histological grade and VEGF and VEGFR-1 overexpression (p<0.001 and p<0.001, respectively). The 5-year DFS of patients with VEGF and VEGFR-1 overexpression was significantly lower than that of those with a weakly positive or negative tumor (p<0.001). Conclusion: Immunohistochemical evaluation of VEGF and VEGFR-1 overexpression may be a useful marker for predicting 5-year DFS in endometrioid endometrial cancer.
Get Citation

Keywords

VEGF, VEGFR-1, VEGFR-2, endometrial cancer, diseasse free survival

About this article
Title

Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer

Journal

Ginekologia Polska

Issue

Vol 81, No 6 (2010)

Bibliographic record

Ginekol Pol 2010;81(6).

Keywords

VEGF
VEGFR-1
VEGFR-2
endometrial cancer
diseasse free survival

Authors

Bożena Dobrzycka
Sławomir Jerzy Terlikowski
Marcin Kwiatkowski
Magdalena Grabowicz
Maciej Kinalski
Lech Chyczewski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl